Elanco Animal Health (NYSE:ELAN - Get Free Report) had its target price raised by Barclays from $30.00 to $32.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's price objective would suggest a potential upside of 19.27% from the stock's previous close.
ELAN has been the topic of a number of other research reports. Jefferies Financial Group downgraded Elanco Animal Health from a "buy" rating to a "hold" rating and lowered their price target for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. JPMorgan Chase & Co. increased their price objective on Elanco Animal Health from $33.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, November 9th. Morgan Stanley reduced their price objective on Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, October 29th. UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, The Goldman Sachs Group started coverage on Elanco Animal Health in a research report on Friday, October 16th. They issued a "buy" rating and a $32.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.36.
View Our Latest Stock Report on ELAN
Elanco Animal Health Price Performance
Shares of NYSE:ELAN traded up $0.13 during trading on Thursday, reaching $26.83. The company had a trading volume of 538,120 shares, compared to its average volume of 5,579,363. The company has a fifty day moving average of $23.52 and a two-hundred day moving average of $23.91. The stock has a market capitalization of $13.41 billion, a P/E ratio of -89.74, a price-to-earnings-growth ratio of 2.19 and a beta of 1.73. Elanco Animal Health has a 12 month low of $19.40 and a 12 month high of $27.98. The company has a current ratio of 2.09, a quick ratio of 1.07 and a debt-to-equity ratio of 0.55.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The firm had revenue of $1.26 billion for the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter last year, the company posted $0.19 EPS. The business's quarterly revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts forecast that Elanco Animal Health will post 1.18 earnings per share for the current year.
Insider Activity at Elanco Animal Health
In related news, insider Timothy Bettington sold 4,350 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the transaction, the insider owned 138,911 shares of the company's stock, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.14% of the company's stock.
Institutional Trading of Elanco Animal Health
Hedge funds have recently added to or reduced their stakes in the business. Algert Global LLC increased its holdings in shares of Elanco Animal Health by 43.6% in the third quarter. Algert Global LLC now owns 259,080 shares of the company's stock worth $5,801,000 after buying an additional 78,650 shares during the period. Allworth Financial LP boosted its holdings in Elanco Animal Health by 13.6% during the 3rd quarter. Allworth Financial LP now owns 9,790 shares of the company's stock valued at $219,000 after acquiring an additional 1,174 shares during the period. Ausdal Financial Partners Inc. boosted its holdings in Elanco Animal Health by 7.1% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 24,521 shares of the company's stock valued at $549,000 after acquiring an additional 1,618 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 15.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,635,234 shares of the company's stock valued at $36,613,000 after acquiring an additional 223,044 shares during the period. Finally, Worldquant Millennium Advisors LLC purchased a new stake in Elanco Animal Health during the 3rd quarter valued at about $4,837,000. 97.48% of the stock is owned by institutional investors.
About Elanco Animal Health
(
Get Free Report)
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.